Abstract
In Reply.— Drs Steinherz and Miller have questioned our failure to consider vincristine as an antiplatelet agent and statement in our recent article that action of Vinca alkaloid on platelet function is unknown. They cite their publication 1 as evidence for in vivo antiplatelet effect of vincristine, which they suggest accounts for therapeutic effect in TTP observed by us. They described an inhibition of second-phase platelet aggregation to epinephrine and ADP, but found collagen-induced aggregation unimpaired, in a large percentage of children receiving multidrug therapy, including vincristine, for leukemia and solid tumors. In their patients with leukemia, platelet function was abnormal before administration of vincristine. We do not interpret these data as proof of a significant antiplatelet effect of vincristine. In their article in British Journal of Haematology , 1 authors cautiously stated on page 447 that the findings seem to be related to
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
